NEW YORK, NY, Sept. 21, 2015 (GLOBE NEWSWIRE) -- Provista Diagnostics, Inc., a privately-held molecular diagnostics company developing and commercializing a new generation of proprietary blood-based diagnostic, prognostic, and monitoring tests designed to address the unmet needs in cancers affecting women including breast and gynecologic cancers, today announced the reelection of the company's Board of Directors.
"The reelection of the Board of Directors demonstrates the ongoing commitment to our business, product, and development in women's health," said David E Reese, Ph.D., President and CEO of Provista.
The members of the Company's Board of Directors are as follows: Anne Busquet, Jeffrey R. Gilman, Robert J. Hariri M.D., Ph.D., Jack Levine CPA, John Macaskill, Thomas G. Mendell, David E. Reese, Ph.D., Yoji Nimura and John Zicarelli Ph.D., FCAS, CFA. Voted by an overwhelming majority, the shareholders of the Company's preferred and common stock re-elected all of the nominees as Directors of the Company to serve until the 2016 Annual Meeting of Stockholders. The election took place at Provista's 2015 Annual Meeting of Stockholders held last week in New York City.
About Provista Diagnostics, Inc.
Provista Diagnostics is a privately held molecular diagnostics company focused on developing and commercializing a new generation of proprietary blood-based diagnostic, prognostic and monitoring tests designed to address the unmet needs in women's cancer, such as breast and gynecologic cancers. Provista Diagnostics' state-of-the-art, high complexity clinical laboratory is accredited by the College of American Pathologists (CAP) and certified by the Centers for Medicare and Medicaid Services (CMS) to be compliant with the Clinical Laboratory Improvement Amendments (CLIA).
Additional information about Provista Diagnostics is available at ProvistaDx.com
Information about Provista Diagnostics' clinical trials is available at ClinicalTrials.gov
Safe Harbor Statement
Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Provista's actual results may differ materially due to a number of factors, many of which are beyond Provista's ability to predict or control, including among others, viability and effectiveness of our sales approach and overall marketing strategies, the outcome of development or regulatory review of our products, commercial success or acceptance by the medical community, competitive responses, our ability to raise additional capital, and the ability to successfully file a registration statement with the SEC. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. Provista operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Provista undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.
CONTACT: David R. Holmes Provista Diagnostics, Inc. IR@ProvistaDx.com (212) 202-3170
Source:Provista Diagnostics, Inc.